Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MIF | P14174 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.36 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010003 | 0.91 | MAPT (0.46) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL2013568 | 0.83 | ITGB3 (0.39) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL2007667 | 0.80 | MIF (0.41) | RAB9AKMT2AMEN1MAPTKDM4E | |
| SCHEMBL2010749 | 0.80 | MIF (0.39) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL2006234 | 0.80 | MIF (0.41) | RAB9AKMT2AMEN1MAPTKDM4E | |
| SCHEMBL2009805 | 0.79 | AOC3 (0.41) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL2008615 | 0.77 | ITGB3 (0.43) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL2007989 | 0.77 | AOC3 (0.46) | KMT2AMEN1MAPTKDM4EAOC3 | |
| SCHEMBL2015632 | 0.77 | ITGB3 (0.53) | AOC3 | |
| SCHEMBL2012689 | 0.77 | ALK (0.45) | KMT2AMEN1MAPTAOC3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
| EP-1677783-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | Nicholas Piramal India Limited (IN) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005035495-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | NPC1 4226/4885RAB9A 2816/4885KMT2A 4561/4885 |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | NPC1 4226/4885RAB9A 2816/4885KMT2A 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.